Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer

The specific primary aim of this study is to evaluate the efficacy of EUS-CPN + analgesic therapy (Group 1) in pain relief of patients with unresectable pancreatic cancer when compared with analgesic therapy (Group 2). The hypothesis will be tested by comparing the changes in reported pain severity between those who receive EUS-CPN in addition to analgesic therapy as compared to analgesic therapy alone.

The secondary aims of this study are to evaluate the efficacy of EUS-CPN + analgesic therapy in improvement of quality of life (QOL) of patients with unresectable pancreatic cancer when compared to when compared with analgesic therapy alone, compare pain medication usage between Group 1 when compared to Group 2, and compare the referral for rescue block during the course of the study between Group 1 and Group 2

Inclusion criteria

• Male or Female
• Age ≥19 yrs old
• Abdominal pain typical for pancreatic cancer ≥3/10
• Abdominal CT radiologically consistent with the diagnosis of pancreatic cancer
• Pancreatic cancer confirmed by FNA during EUS
• Inoperability of pancreatic cancer as determined during EUS or prior CT

Exclusion criteria

• Age < 19 yrs old
• Unable to safely undergo EUS for any reason
• Coagulopathy (prolongation of prothrombin time > 18 sec, thrombocytopenia <80,000 platelets/ml)
• Previous CPN or other neurolytic block that could affect pancreatic cancer -related pain or had implanted epidural or intrathecal analgesic therapy
• Another cause for abdominal pain such as pseudocyst, ulcer or other intra-abdominal disorder
• Potential patient noncompliance (refusing to follow schedule of events)
• Active alcohol or other drug use or significant psychiatric illness
• Pregnant or breastfeeding
• Unable to consent
• Non-English speaking